Shares of BioAge Labs Inc. (BIOA) plummeted over 60% in after-hours trading on Friday, following the company's decision to discontinue its ongoing STRIDES study.
STRIDES is a phase II trial evaluating the company's lead drug candidate Azelaprag in combination with Eli Lilly's weight management drug tirzepatide for obesity.
The decision to discontinue the trial was taken after liver transaminitis without clinically significant symptoms was observed in some subjects receiving Azelaprag. No transaminase elevations were observed in the Tirzepatide-only treatment group.
Transaminitis occurs when the levels of specific liver enzymes, called transaminases, are elevated in the blood. This typically signals that the liver is inflamed or has suffered damage.
The STRIDES study has enrolled 204 subjects to date, of which 11 individuals in the Azelaprag treatment group show elevated transaminase levels, with no clinically significant symptoms, the company said.
The topline results from the STRIDES study were initially expected in the third quarter of 2025. However, with the company deciding to discontinue the trial, the revised plans for azelaprag are now expected to be announced in Q1 2025.
BioAge made its debut on the Nasdaq Global Select Market on September 26, 2024, pricing its shares at $18 each.
BIOA has thus far hit a low of $16.30 and a high of $26.62. The stock closed Friday's trading at $20.09. In after-hours the stock crashed more than 67% to $6.60.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.